ID Connect’s clinical consultant Erin McCreary, PharmD, BCPS, BCIDP, commented on the demise of Evusheld in Time Magazine’s Feb. 8, 2023, online edition. The article, titled “Without Evusheld, Immunocompromised People Are on Their Own Against COVID-19,” explores the effects of the end of the pandemic emergency declarations in May 2023 and the FDA’s revoked emergency-use authorization of Evusheld, a therapy first authorized in Dec. 2021.
You might also like…
ID Connect Named “Telehealth Company to Know” by Becker’s Hospital Review
How a Comprehensive Telemedicine Service Model Can Cover an Entire Health Network
Today’s Ever-Changing Physician: CEO and Co-Founder Rima Abdel Massih, M.D., Featured in Becker’s